This is partly because most investigations on the pro-tumorigenic role of CDK12 employed already transformed breast cancer cell lines, often bearing CDK12 and HER2 co-amplification, thus confounding the role of CDK12 as a primary oncogene. This evidence concerns the gene ERBB2 and breast carcinoma.